Results 61 to 70 of about 82,478 (265)
Cancer Immunology and Immunotherapy, 2021 This work investigated the clinical prognostic implications and biological function of plasma soluble programmed cell death ligand 1 in breast cancer patients.
Baojuan Han +10 more
semanticscholar +1 more source
Journal of Hematology & Oncology, 2016 Background Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus (EBV)-associated, highly aggressive lymphoma. Treatment outcome remains sub-optimal, especially for advanced-stage or relapsed diseases.
Xi-wen Bi +9 more
doaj +1 more source
Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1 [PDF]
Journal of Translational Medicine, 2020 AbstractBackgroundPrevious studies have shown clinical relevance of programmed death-ligand 1 (PD-L1) and soluble PD-L1 (sPD-L1) in human cancers. However, still contradictory results exist. Our aim was evaluation of PD-L1-expressing monocytic myeloid-derived suppressor cells (M-MDSCs), monocytes/macrophages (MO/MA), tumour cells (TC) and immune ...
Karolina Okła +8 more
openaire +3 more sources
, 2017 Autologous hematopoietic stem cell transplantation (AuHSCT) is standard in treating eligible multiple myeloma (MM) patients. However, the outcome after treatment is highly variable.
Huang, Shang-Yi;Lin, Hsiu-Hsia;Lin, Chung-Wu;Li, Chi-Cheng;Yao, Ming;Tang, Jih-Luh;Hou, Hsin-An;Tsay, Woei;Chou, Sheng-Je;Cheng, Chieh-Lung;Tien, Hwei-Fang +1 more
core +1 more source
, 2022 Soluble and exosomal programed death-ligand 1 (PD-L1) can be upregulated in extranodal natural killer/T-cell lymphoma (ENKTL). However, its clinical role in predicting outcomes after pembrolizumab treatment has yet to be studied in ENKTL patients.
Kim, Seok Jin +13 more
core +1 more source
Frontiers in Immunology, 2023 Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of multiple cancer types including lung cancer, which is a leading cause of cancer death in the world.
Luyao Wang +12 more
doaj +1 more source
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
Oncotarget, 2017 The membrane-bound molecules programmed death 1 (PD-1) and its ligand PD-L1 (PD-1/PD-L1) belong to the immune checkpoint pathway. PD-1 pathway downregulates effector T cells in immune response, thereby causing immune suppression. Recent studies have revealed that membrane-bound PD-1 and PD-L1 also have soluble forms.
Zhu, Xinxin, Lang, Jinghe
openaire +3 more sources
PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment [PDF]
Scientific Reports, 2016 AbstractMyeloid-derived suppressor cells (MDSCs) could have important roles in immune regulation, and MDSCs can be induced in patients with various malignant tumors. The immune-suppressive functions of MDSCs in hepatocellular carcinoma (HCC) patients have not been clarified.
Tomoaki Iwata +9 more
openaire +2 more sources
Predicting treatment response of patients with extranodal natural killer/T‐cell lymphoma based on levels of
Hematological Oncology, 2020 Abstract Appropriate biomarkers may help predict patient response to treatment for extranodal natural killer/T‐cell lymphoma (ENKTL), a subtype of non‐Hodgkin's lymphoma in China. Programmed cell death receptor 1 (PD‐1) and its ligand (PD‐L1) have been investigated in various tumors.
Yu Feng +4 more
openaire +2 more sources
Journal of atherosclerosis and thrombosis, 2023 Aims: Programmed cell death-1 (PD-1) and its ligand (PD-L1) regulate T cells, leading to immunotolerance. We previously demonstrated that patients with coronary artery disease (CAD) had increased circulating levels of soluble PD-L1 (sPD-L1). However, the
Shuhei Miyazaki +15 more
semanticscholar +1 more source